0001209191-24-000780.txt : 20240104 0001209191-24-000780.hdr.sgml : 20240104 20240104162530 ACCESSION NUMBER: 0001209191-24-000780 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wassil Jim CENTRAL INDEX KEY: 0001813798 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 24512284 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 353 HATCH DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-02 0 0001649094 Vaxcyte, Inc. PCVX 0001813798 Wassil Jim C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 0 1 0 0 Chief Operating Officer 1 Common Stock 2024-01-02 4 M 0 3000 2.42 A 178935 D Common Stock 2024-01-02 4 S 0 289 62.71 D 178646 D Common Stock 2024-01-02 4 S 0 1039 63.547 D 177607 D Common Stock 2024-01-02 4 S 0 1562 64.293 D 176045 D Common Stock 2024-01-02 4 S 0 110 65.15 D 175935 D Stock Option (right to buy) 2.42 2024-01-02 4 M 0 3000 0.00 D 2029-12-16 Common Stock 3000 93555 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $62.01 to $62.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $63.13 to $63.885. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $64.13 to $64.99. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Jim Wassil, by /s/ Ron A. Metzger, Attorney-in-Fact 2024-01-04